Loading... Please wait...
Contact Us
Would you like more
information on this report
Please contact us today at +44(0)20.7665.9240
or +1 212.220.0880
or write to us.

Glioblastoma: Update Bulletin #3 [November 2018]

Product Code:
596200990
Publication Date:
November 2018
Format:
PDF
Price:
$1,315

This edition presents the views and insights from three key opinion leaders (KOLs) from North America and Europe on a variety of recent events in the glioblastoma multiforme (GBM) market. Within this update, KOLs provided their views on the following key events: VBI Vaccines announcing that an Independent Data and Safety Monitoring Board (DSMB) has completed its second safety assessment of the ongoing Phase I/IIa fully enrolled study of VBI-1901 in recurrent GBM; Moleculin Biotech announcing initiation of a Phase I clinical trial of WP1066, a novel JAK2/STAT3 inhibitor, in patients with recurrent malignant glioma; and DelMar Pharmaceuticals providing clinical updates on the Phase II development of VAL-083 (dianhydrogalactitol), a novel DNA targeting agent.

Business Questions:

• DO KOLs believe that vaccine-based treatment approaches are likely to show any clinical efficacy in GBM?
• Do KOLs believe that CMV and its association with GBM, is a logical target when developing vaccine-based treatments for GBM?
• If successful, how will VBI-1901be used in the treatment of GBM?
• How important is STAT3 in the pathogenesis of GBM, and what potential does WP1066 have as a future treatment option?
• Do KOLs have any safety concerns for WP1066?
• What likelihood do KOLs think WPI1066 has in becoming a treatment option for GBM, and how could it be used in the GBM treatment paradigm?
• How important is VAL-083’s ability to overcome chemotherapy resistance and satisfy a critical unmet need in the treatment of GBM?
• What do KOLs think about the design and primary outcome measures for VAL-083’s Phase II clinical trials?
• Do KOLs have any safety concerns for VAL-083?
• Subject to approval, how and when will VAL-083 be used as a treatment for GBM?





customer.service@firstwordpharma.com

All Contents Copyright © 2019 Doctor's Guide Publishing Limited All Rights Reserved